Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Molecular correlates of nivolumab outcomes in RCC

Yann-Alexandre Vano describes a translational analysis of the NIVOREN GETUG-AFU 26 trial to identify biomarkers associated with outcomes in nivolumab-treated patients with metastatic clear cell renal cell carcinoma (3:29).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript


This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Related content

26-06-2019 | Renal cell carcinoma | News

Nivolumab has ‘limited’ CNS activity in RCC patients with brain metastases

30-09-2019 | Renal cell carcinoma | Video | Article

Expert comment: RCC immunotherapy – biomarker round-up
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits